Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Convertible Debt: 2019-2025

  • China SXT Pharmaceuticals' Convertible Debt rose 94.04% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 94.04%. This contributed to the annual value of $2.8 million for FY2024, which is 10.15% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Convertible Debt stood at $2.8 million for Q3 2025, which was up 94.04% from $1.5 million recorded in Q3 2024.
  • China SXT Pharmaceuticals' 5-year Convertible Debt high stood at $3.1 million for Q1 2023, and its period low was $1.5 million during Q3 2024.
  • Its 3-year average for Convertible Debt is $2.6 million, with a median of $2.8 million in 2025.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Convertible Debt decreased by 10.15% in 2024, and later soared by 94.04% in 2025.
  • Quarterly analysis of 3 years shows China SXT Pharmaceuticals' Convertible Debt stood at $3.1 million in 2023, then decreased by 10.15% to $1.5 million in 2024, then spiked by 94.04% to $2.8 million in 2025.
  • Its Convertible Debt stands at $2.8 million for Q3 2025, versus $1.5 million for Q3 2024 and $2.8 million for Q1 2024.